Daily Stock Setups

Helicos BioSciences Sells Helicos Genetic Analysis System to Leiden University Medical Center in the Netherlands

Posted on: Sat, 21 Nov 2009 22:47:00 EST

Symbols: HLCS

Are you looking to increase your ETF knowledge?

Nov 20, 2009 (Close-Up Media via COMTEX) --
HLCS | Quote | Chart | News | PowerRating -- Helicos BioSciences announced the sale of a Helicos Genetic Analysis System to a collaborative Dutch research group led by the Leiden University Medical Center (LUMC), further including the medical centers of Amsterdam (AMC) Groningen (UMCG) and Rotterdam (Erasmus MC) and funded by a grant from NWO, the Netherlands Organization of Scientific Research.

According to Helicos, the system will be installed at the Leiden Genome Technology Center (LGTC), headed by Professor Johan den Dunnen, a developer of genomic research and technology.

"We are very proud to have LUMC as a customer," said Ron Lowy, Helicos CEO. "They have a tradition of adopting breakthrough technologies and have seen the benefits of single molecule analysis first-hand."

The relationship between the medical center and Helicos began with a collaboration in which researchers at the LUMC's Forensic Laboratory (FLDO) provided the company with ancient human DNA samples for analysis using Helicos' True Single Molecule Sequencing (tSMS) technology. Unlike alternative, amplification-based, next-generation sequencing technologies, Helicos' tSMS approach provided informative human sequences from these ancient remains, demonstrating the technology's ability to analyze degraded and compromised DNA samples. The project was led by Professor Peter de Knijff and graduate student Eveline Altena. The resulting data were reported at various conferences in September and October of 2009, including at the American Society of Human Genetics Conference in Honolulu. The data are being prepared for publication.

The Helicos Genetic Analysis System is a commercially available, single molecule sequencing technology, and enables scientists to conduct studies in the fields of genome biology, cancer research, common diseases, and microbiology without DNA ligation or amplification. Genetic analysis with Helicos' technology eliminates the biases, complexity and errors introduced by DNA amplification, requires minute amounts of starting material, is amenable to the analysis of degraded nucleic acids, and provides the most direct and accurate view of biological samples.

Helicos BioSciences is a life science company focused on genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing, tSMS, technology allows direct measurement of billions of strands of DNA.

((Comments on this story may be sent to newsdesk@closeupmedia.com))

For full details on Helicos Biosciences (HLCS) HLCS. Helicos Biosciences (HLCS) has Short Term PowerRatings at TradingMarkets. Details on Helicos Biosciences (HLCS) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.